Bumetanide: Clinical Trials

6 trials of Bumetanide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 recruiting, 2 terminated, 1 completed, 1 withdrawn. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Recruiting 2, Terminated 2, Completed 1, Withdrawn 1

Follow Bumetanide: new trials by email Literature Review of Bumetanide trials Research Report on Bumetanide

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bumetanide vs. Furosemide in Cirrhosis
Bumetanide, Furosemide - Cirrhosis
Phase 3RecruitingStacy Johnson5002026-06-032026-06-16
Role of Bumetanide in Treatment of Autism
Bumetanide, Placebo - Autism
Phase 3RecruitingSherief Abd-Elsalam802021-01-012021-02-23
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52 - Autism Spectrum Disorder (ASD)
Phase 3TerminatedInstitut de Recherches Internationales Servier2112018-10-042023-06-05
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
Bumetanide Oral Solution, Placebo - Autism Spectrum Disorder (ASD)
Phase 3TerminatedInstitut de Recherches Internationales Servier2112018-09-242024-07-25
Bumetanide Versus Furosemide in Heart Failure
Furosemide, Bumetanide, furosemide - Heart Failure
Phase 3WithdrawnLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's2011-01-012014-03-27
Efficiency of Bumetanide in Autistic Children
bumetanide - Autistics Children
Phase 3CompletedUniversity Hospital, Brest602010-03-012011-12-21

Conditions studied

Autism Spectrum Disorder (2)  ·  Autistic Disorder (2)  ·  Edema (1)  ·  Fibrosis (1)  ·  Heart Failure (1)  ·  Insulin Resistance (1)

Sponsors

Institut de Recherches Internationales Servier (2)  ·  London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)  ·  Sherief Abd-Elsalam (1)  ·  Stacy Johnson (1)  ·  University Hospital, Brest (1)

Countries

France (3)  ·  Brazil (2)  ·  Hungary (2)  ·  Italy (2)  ·  Poland (2)  ·  Portugal (2)  ·  Spain (2)  ·  United Kingdom (2)  ·  United States (2)  ·  Australia (1)  ·  Canada (1)  ·  Czechia (1)  ·  Egypt (1)  ·  Germany (1)  ·  Netherlands (1)

Top investigators

Abeer Salamah, Dr (1)  ·  Esraa Shaker, Msc (1)  ·  Neville G Suskin, MBChB, MSc (1)  ·  Osama Elagamy, Prof (1)  ·  Stacy A Johnson, MD (1)

Results publications

PMID 39816573, PMID 23233021, PMID 37794745

NIH funding

2017 (2)